Astellas is rolling out its first DTC campaign to raise awareness about an injection that treats geographic atrophy.

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...

Astellas Pharma is slowing things down in the inaugural consumer-facing marketing blast for eye disease drug Izervay. | ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Şeyma will report directly to the President of International Markets and will be based in Istanbul. As a member of the ...

The Federal Circuit vacated a decision axing an Astellas Pharma Inc. drug patent based on an argument not presented at trial ...

Singlera Genomics and Astellas Pharma presented results during the JSOT 2024 Annual Meeting demonstrating that drug-induced ...

The Federal Circuit has vacated a District of Delaware ruling in a patent case which found that patent claims asserted by ...

Astellas is ready to launch its first digital health offering in the US, a toolkit dedicated to providing at-home monitoring ...

In a news packed morning, Japanese drugmaker Astellas Pharma (TYO: 4503) today revealed two regulatory approvals.

The US Food and Drug Administration (FDA) has listed Astellas Pharma’s non-invasive digital health solution, DIGITIVA, ...

Astellas Pharma’s claudin 18.2-directed cytolytic antibody has been approved by the European Commission (EC) as part of a first-line combination treatment for a subset of gastric cancer patients.